Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Physician &Crohn’s Disease and Ulcerative Colitis: U.S. Physician and Payer Perspectives on Established and Recently Launched Biologics, Emerging Novel Agents and Biosimilars | Payer Forum | US | 2014
Crohn’s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune/inflammatory indications that commonly feature treatment with biological therapies. The U.S. CD market…
Biosimilars Advisory Service: Acceptance of Biosimilars Across Physician Specialties | Biosimilars Advisory Service | US/EU | 2014
The fledgling biosimilars industry is full of uncertainties and nuances that differ by country, therapeutic specialty, and molecule. Securing a positive return on lengthy biosimilar development…
Autoimmune Diseases ( High-Cost Biologics for Autoimmune Diseases: How Will Healthcare Reform and Payer-Led Cost-Taming Strategies Impact Brand Prescribing? ) | Physician & Payer Forum | US | 2014
As the pharmaceutical pipeline begins to churn out specialty products at a higher rate than traditional therapies, the nation’s healthcare payers are experiencing double-digit growth in their…
Global Biosimilars Markets (Regulations, Pipelines and Major Players) | Biosimilars Advisory Service | US/EU5/Asia Pacific | 2014
The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 80% of branded biologics sales, the rest-of-world segment includes many…
